Fig 2.

Patient-derived xenografts (PDXs) confirm the prediction of PANOPLY (Precision Cancer Genomic Report: Single Sample Inventory) that olaparib is an effective treatment of a patient with chemotherapy-resistant triple-negative breast cancer (TNBC; patient BC_051_1_1). (A) The top panel shows histologic stains of the patient’s tumor and PDXs (before and after treatment). (B) Cytotoxicity data show the PDX response to the top predicted drug olaparib compared with no treatment. (The left plot shows the olaparib drug response data from pretreatment mice, whereas the right plot shows the data from post-treatment PDX models. Both of the data sets were generated using the vehicle as controls.) ER, estrogen receptor; H&E, hematoxylin and eosin; HER2, human epidermal growth factor receptor 2; Ki67, marker to measure proliferative index; PostNAC, post neoadjuvant chemotherapy; PR, progesterone receptor; PreNA, pre neoadjuvant chemotherapy